Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors. // Clinical Colorectal Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S1533002826000307?dgcid=rss_sd_all
Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors. Clinical Colorectal Cancer. https://www.sciencedirect.com/science/article/pii/S1533002826000307?dgcid=rss_sd_all
“Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors.” Clinical Colorectal Cancer.
@article{article40598,
title = {Dual CTLA-4/PD-1 Blockade Versus Anti–PD-1 in MSI-H Metastatic Colorectal Cancer: Early Survival Benefit and Exploratory Clinical Predictors},
journal = {Clinical Colorectal Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S1533002826000307?dgcid=rss_sd_all}
}